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In periodontal disease, host recognition of bacterial constituents, including lipopolysaccharide (LPS), induces p38 MAPK
activation and subsequent inﬂammatory cytokine expression, favoring osteoclastogenesis and increased net bone resorption in
the local periodontal environment. In this paper, we discuss evidence that the p38/MAPK-activated protein kinase-2 (MK2)
signaling axis is needed for periodontal disease progression: an orally administered p38α inhibitor reduced the progression
of experimental periodontal bone loss by reducing inﬂammation and cytokine expression. Subsequently, the signiﬁcance of
p38 signaling was conﬁrmed with RNA interference to attenuate MK2-reduced cytokine expression and LPS-induced alveolar
bone loss. MAPK phosphatase-1 (MKP-1), a negative regulator of MAPK activation, was also critical for periodontal disease
progression. In MPK-1-deﬁcient mice, p38-sustained activation increased osteoclast formation and bone loss, whereas MKP-
1 overexpression dampened p38 signaling and subsequent cytokine expression. Finally, overexpression of the p38/MK2 target
RNA-binding tristetraprolin (TTP) decreased mRNA stability of key inﬂammatory cytokines at the posttranscriptional level,
thereby protecting against periodontal inﬂammation. Collectively, these studies highlight the importance of p38 MAPK signaling
in immune cytokine production and periodontal disease progression.
1. InnateImmunityand PeriodontalDisease
1.1. Host-Microbe Interaction. Within the oral cavity exists
a bioﬁlm colonized by more than 500 diﬀerent microbial
species, very few of which are actually associated with
periodontal disease [1–3]. These periopathogenic gram-
negative bacteria contain multiple virulence factors, includ-
ing lipopolysaccharide (LPS), which can induce the host
inﬂammatory response. In periodontal diseases initiation
and progression, such an inﬂammatory response to bacterial
bioﬁlmisexaggerated,resultinginleadingtooverproduction
of inﬂammatory cytokines that cause gingival inﬂammation,
bleeding, extracellular matrix degradation, bone resorption,
and tooth loss [4–6].
Over the past two decades, how host-microbe interac-
tions contribute to both disease initiation and associated
tissue destruction have been elucidated. Epidemiological
data indicate diﬀerent intraindividual susceptibilities to
periodontal disease, despite the long-term presence of
oral bioﬁlm [7–9]. Moreover, increased susceptibility and
greater severity of periodontal disease were observed in
individuals with impaired immune responses [10, 11]. The
most signiﬁcant development in periodontitis research has
been the fundamental role of innate immunity in initiating
immuneresponsesandregulatingadaptive(antigen-speciﬁc)
responses [5]. The innate immune response recognizes and
responds to all colonizing microbes, both commensal and
pathogenic. The modest cytokine response to commensal
bacteria stimulation in the periodontium is necessary for
priming host immunity and maintaining tissue integrity,
and the ampliﬁed immune response is induced when the
microbial composition of plaque, in which pathogenic
bacteria are greatest, changed [12, 13].
In the current paradigm, Toll-like receptors (TLRs) link
the host and microbes and are considered essential for
LPS-induced signaling. LPS, one of the main pathogen-
associated molecular patterns (PAMPs) of pathogenic bac-
teria, is recognized by the host through TLRs, resulting2 Journal of Signal Transduction
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Figure 1: Pattern recognition receptors and innate immune signaling. TLR-2, TLR-4, and TLR-9 are depicted as examples of TLR receptors
expressed in cells of the periodontal tissues. Upon ligand binding, all TLRs (except TLR3) recruit adaptor protein MyD88 and activate com-
mon upstream activator (IRAK/TRAF6 and TAK1) of NF-kB and MAP kinases. TLR-4 may also activate NF-kB independent of MyD88 and
with delayed kinetics (red dotted line). Nod1/Nod2 are cytosolic PRRs that recognize peptidoglycan fragments of the bacterial wall and may
amplify TLR-induced activation of signaling pathways. Activated NF-kB and MAP kinases translocate to the nucleus and bind to their motifs
(NF-kB, AP-1, resp.) in the promoter of target genes (including early-response and inﬂammatory genes) and induce their transcription into
mRNA which will ultimately lead to increased cytokine production. p38 MAP kinase also involved posttranscriptional regulation of pro-
inﬂammatory genes (for example, IL-6, Cox-2) by modulation of mRNA stability in the cytoplasm. (TLR: toll-like receptor, CD14: cluster
of diﬀerentiation 14 molecule; MD2: myeloid diﬀerentiation protein 2; MyD88: myeloid diﬀerentiation primary response gene 88; IRAK:
interleukin-1 receptor-associated kinase; TRAF6: TNF receptor associated factor 6; TAK1: TGF-beta activated kinase 1; MKK: mitogen-
activated protein kinase kinase; ERK: extracellular signal-regulated kinase: JNK: c-Jun N-terminal kinase; AP-1: activator protein-1).
in activation of multiple downstream cell signaling cas-
cades [14]. To date, the TLR family includes 13 members,
which is consistent with the range of PAMPs expressed
by infective microorganisms. These receptors not only
recognize various PAMPs and activate innate immune
response, but they can also bind to endogenous molecules
derived from damaged tissue and contribute to innate
inﬂammation as well as the adaptive immune response [15].
Within the periodontium, innate immunity is comprised
of resident immune cells such as monocytes/macrophages,
neutrophils, dendritic cells, and nonimmune resident cells
such as periodontal ﬁbroblasts and gingival epithelial cells.
Accordingly, all of these cell types express various TLRs
to identify and respond temporarily to PAMPs [16–18].
In periodontal tissues, TLR2 and TLR4 expression has
been positively correlated with disease severity, suggesting
that these receptors have an increased capacity to signal
and inﬂuence downstream cytokine expression [19–21]. All
TLRs are single-pass transmembrane proteins containing a
commonextracellularN-terminalleucine-richdomainanda
conserved intracellular C-terminal domain. The N-terminal
domain is responsible for the recognition of the ligands
and the C-terminal tail is shown to be homologous with
the intracellular domain of the interleukin-1 receptor type
I, currently designated as the Toll/IL-1 receptor (TIR)
domain [22]. The classic intracellular signaling pathways
activated by TLR engagement are highly conserved. The
TLR-PAMP interaction recruits speciﬁc adaptor molecules
which then bind the interleukin (IL)-1 receptor associated
kinase (IRAK), initiating a chain of signaling transduction.
In the TLR pathway, at least four adaptor proteins, includ-
ing myleloid diﬀerentiation primary-response protein 88
(MyD88), TIR domain-containing adaptor-inducing inter-
feronβ (TRIF),MyD88adapter-like/TIRdomain-containing
adaptor protein (Mal/TIRAP), and TRIF-related adaptor
molecule (TRAM), contain TIR domains that can be
recruited by activated TLRs. Each of these adaptor molecules
interact with the various TLRs, an event thought to be
responsible forsignaltransductionbranchingandsigniﬁcant
TLR signaling ﬂexibility by allowing crosstalk with other
pathways, including MAP kinase, PKR, and Notch pathways
[23–27] (see Figure 1).Journal of Signal Transduction 3
Of the TLR signaling pathways, the most studied is the
recognition of LPS by a macromolecular complex involving
CD14, MD2, and TLR4 [6, 28, 29]. In response to LPS, com-
plex formation triggers MyD88 and, in turn, recruits IRAK
and TRAF6. The phosphorylated IRAK/TRAF6 complex
then dissociates from the receptor complex to a new complex
with transforming growth factor β-activated kinase (TAK1)
along with TAK-1 and -2 binding proteins (TAB1 and -2)
which phosphorylate TAK1. TAK1, in turn, phosphorylates
both the inhibitor of nuclear factor κB-(IκB-) kinase com-
plex (IKK complex) and mitogen-activated protein kinase
(MAPK) kinases-3 and -6 (MKK3, MKK6) [30]. The IKK
complex then phosphorylates IκB, which allows nuclear
factor-kappa B (NF-kB) transcription factors (p50/p65) to
translocate to the nucleus and bind to the promoter regions
of many proinﬂammatory cytokine and chemokine genes
and activate their transcription [31, 32]. Similarly, MKK3/6
can phosphorylate p38 and c-jun N-terminal kinase (JNK)
MAPK to activate activator protein-1 (AP-1) transcription
factors (TFs) and initiate gene expression. In addition, p38
can phosphorylate RNA-binding proteins, which can stabi-
lize cytokine mRNA and thus amplify cytokine production
[33], as depicted in Figure 1.
1.2. Genesis of Inﬂammation in Periodontal Tissues. Peri-
odontal tissue destruction is initiated by pathogens that col-
onize in the periodontal pocket, a unique microenvironment
in the subgingiva that fosters the growth of anaerobic bacte-
ria and spirochetes. These microorganisms produce harmful
byproducts and enzymes, such as collagenases and proteases,
which degrade the extracellular matrix to produce nutrients
for their growth. Resultant tissue damage creates pathways
for invasion, followed by irritation and inﬂammation of host
tissues, eliciting a host immune response. This local immune
response in gingival tissues involves recruitment of inﬂam-
matory cells, generation of cytokines and prostanoids, elab-
oration of lytic enzymes, and osteoclast activation [34–36].
Within the inﬂamed periodontium exist various resident
immune and nonimmune cells: periodontal ligament cells,
ﬁbroblasts, osteoblasts, osteoclasts, neutrophils, antigen-
presenting cells such as dendritic cells, macrophages, T cells,
and B cells. These resident cell types recognize and interact
with bacterial constituents (e.g., cytoplasmic membranes,
peptidoglycans, outer membrane proteins, lipopolysaccha-
ride, capsules, and cell-surface ﬁmbriae) to generate proin-
ﬂammatory mediators, such as IL-1, tumor necrosis factor
(TNF)-α, IL-6, and prostaglandin E2 (PGE2)[ 37–39]. These
secreted molecules can recruit more nonresident cells (e.g.,
neutrophils, macrophages, and lymphocytes) to inﬁltrate tis-
sues and initiate the innate immune response [40, 41]. They
also further induce their own expressions through numerous
autocrine or paracrine mechanisms and thus perpetuate
andamplifychronicperiodontalinﬂammation.Additionally,
cellular components and byproducts of tissue breakdown
in the periodontium can be recognized and trigger sig-
nal cytokine secretion, possibly creating a self-sustaining
positive feedback circuit, leading to loss of tissue function
and exacerbated clinical disease. With overexpression of
proinﬂammatory cytokines, other inﬂammatory enzymes
and mediators, such as matrix metalloproteinases (MMPs)
and receptor activator of nuclear factor-kB ligand (RANKL),
are upregulated to produce irreversible soft and hard tissue
damage.
Within periodontal lesions, activated monocytes, macro-
phages, and ﬁbroblasts all produce cytokines, such as TNF-
α,L - 1 β,I L - 6 ,a n dP G E 2, which are signiﬁcantly elevated
in diseased periodontal sites, compared with healthy or
inactive sites [42–48] and have been positively correlated
with increased probing depth and attachment loss [49–51].
In the gingival crevicular ﬂuid, elevated IL-6, TNF-α,a n dI L -
1β were reported in persons aﬄicted with periodontitis [52,
53]. Elevated IL-6 is higher in recurrent periodontitis cases
and increased GCF correlates with gram-negative ﬁmbriae
[53–55].
Periodontaldiseasemanifestsasanintimatecombination
ofinﬂammationandboneresorption,leadingtotheeventual
tooth loss. Bone is a dynamic tissue that constantly under-
goes a remodeling process in which bone resorption and
bone deposition are balanced.When chronic inﬂammation
occurs in bone and other mineralized tissue, this balance is
disrupted to favor net bone loss. In periodontitis, alveolar
bone resorption occurs when inﬂammatory mediators in the
overlying soft tissues reach a certain threshold at a critical
distance from the bone surface and activate pathways leading
to bone resorption [56].
The RANK/RANK ligand (RANKL)/osteoprotegerin
(OPG) system which controls osteoclast development, dif-
ferentiation, activation, and function, is a key mediator of
bone loss in periodontal disease. Through interactions with
its cognate receptor RANK on the cell surface of osteoclasts
and osteoclast precursors, RANKL stimulates diﬀerentiation
and maturation of cells from the monocyte/macrophage
lineage to form functional osteoclasts and then induces
osteoclastogenesis and subsequent bone resorption. OPG,
a soluble member of the tumor necrosis family produced
by osteoblasts, marrow stromal cells, and other cells, can
bind to RANKL as a decoy receptor and inhibit osteoclast
diﬀerentiation to balance this system, decreasing RANKL
functional activity. Thus, the RANKL/OPG ratio eventually
determines bone turnover [6, 57, 58].
Even though RANKL expression may require diﬀerent
signaling pathways depending on the nature of extracellular
stimulation, cell type, and even cell diﬀerentiation state,
RANKL expression has been shown to increase inﬂamed
periodontal tissues from various cell types, including
osteoblastic cells, bone marrow stromal cells, endothelial
cells, mononuclear cells, and periodontal ligament ﬁbrob-
lasts[59–63]. More recently, many secreted proinﬂammatory
cytokines and other mediators have been shown to converge
and stimulate RANKL in these cell types. Meanwhile, most
of these same molecules decreased OPG production. Such
molecules include IL-1β,T N F - α, IL-6, IL-8, IL-11, IL-17,
MMPs,andPGE2,allofwhichareupregulatedinperiodontal
tissues. With alveolar bone loss, the periodontal pocket
deepens and subgingival plaque bioﬁlm further accumulates.
The subgingival microﬂora becomes more anaerobic and the
host response becomes more destructive and chronic.4 Journal of Signal Transduction
2. Pathobiology of Periodontal
DiseaseProgression
2.1. MAPK Cell Signaling. The innate immune system serves
as a ﬁrst defense against invading pathogenic organisms and
its interaction with microbial components activates multiple
signaling cascades, including MAP kinase pathways. Among
the various signaling molecules that regulate inﬂammatory
pathways, kinases are important because their aberrant
or upregulated expression signiﬁcantly contributes to the
regulation of inﬂammatory disease. MAP kinases are highly
conserved serine/threonine protein kinases in eukaryotes.
MAP kinase BMK-1/ERK5 has been reported to respond
to both growth factors and stressful stimuli, contributing
to cell cycle progression and proliferation, but three other
MAP kinases, p38, c-Jun N-terminal kinases JNK, and extra-
cellular signal-regulated kinases ERK, are the most studied
[64].
Diﬀerent cell stimuli preferentially activate distinct MAP
kinases and endow them with diﬀerent functions. Many
growth factor and G protein linked receptors, cell adhesion,
phorbol esters, and some oncogenes are linked to activation
of the ERK MAP kinases, which are involved in cellular
chemotaxis, cell cycle progression and mitogenesis, onco-
genic transformation and metastasis, neuronal diﬀerenti-
ation and survival, and in processes underlying memory
and learning. Inﬂammatory cytokines (such as IL-1 and
TNF-α) ,t r o p h i cf a c t o rd e p r i v a t i o n ,a n dan u m b e ro fc e l l
stress-inducing factors (such as heat shock, osmotic shock,
ultraviolet radiation, and oxygen radicals) preferentially lead
to activation of JNK/SAPK and p38 MAP kinases. In all,
MAPK signal transduction cascades play a pivotal regulatory
role in the biosynthesis of numerous cytokines, chemokines,
and other inﬂammatory mediators that are necessary for the
immune system to combat pathogenic infections.
The MAPKs are organized in modules (MAPKKK→
MAPKK→MAPK) sequentially activated by a cascade of
dual phosphorylation events at tyrosine/threonine residues.
Beginning with the activation of upstream MAP kinase
kinase kinase (MKKK), MAP kinase kinase (MKK) is further
activated by MKKK at two serine residues. MKK in turn
activates MAP kinase by phosphorylating the MAPKs at the
adjacent threonine and tyrosine residues localized within a
conserved activation loop motif, TxY, between the kinase
subdomains VII and VIII (where x represents glutamate in
ERK,prolineinJNK/SAPK,andglycineinp38MAPKs)[65].
Furthermore, MKK-3 and -6 are speciﬁc for p38 whereas
MKK-4 also activates JNKs. Once activated, the MAPKs can
target an array of downstream substrate proteins for phos-
phorylation, including the “downstream” serine/threonine
kinases (which themselves become activated), cytoskeletal
elements, cell death regulators, and many nuclear receptors
and transcription factors (including AP-1 (homodimer or
heterodimer of the proteins c-fos and c-jun), NF-κB, or
CAAT-enhancer-binding protein) which facilitate gene tran-
scription. For example, NF-κB can bind to the promoter
regions of many proinﬂammatory cytokine and chemokine
genes and activate their transcription. In addition to the
regulation of the expression of inﬂammatory mediators,
MAPKs are also implicated in the regulation of reactive
oxygen and nitrogen species, which are critical for killing
microbes engulfed by phagocytes. MAPKs also regulate gene
expression through promoting chromatin remodeling [64]
andparticipateinthetransport,stabilization,andtranslation
ofcytokine mRNAtranscripts thatcontainAU-rich elements
[33]. It is well known that p38 MAPK activates MAP kinase-
activated protein kinase (MK)-2 through phosphorylation.
MK-2, in turn, inactivates transacting RNA-binding protein
tristetraprolin (TTP) by phosphorylation at serine 52 and
178. This phosphorylation sequesters TTP with 14:3:3
and inhibits the binding of TTP with ARE mRNA. Thus,
ARE mRNAs are spared from TTP shuttling to degradation
machinery, and TTP-mediated deadenylation and destabi-
lization of ARE-containing transcripts are inhibited, giving
mRNAs an opportunity for translation [66–68].
Once the inﬂammatory stimulus is resolved, negative
regulators modulate the strength and duration of the acti-
vated MAPK signaling pathway and control the production
of inﬂammatory cytokines, thus restraining the potentially
devastating actions of the immunological system on the host
and preventing self-destruction. These negative regulators
include tyrosine, serine/threonine, and dual speciﬁcity phos-
phatases. A group of dual speciﬁcity protein phosphatases
(often referred to as MAPK phosphatases (MKPs)) [69]a r e
the primary phosphatases responsible for dephosphoryla-
tion/deactivation of MAP kinases (see Figure 2). MKP-1, an
archetypal member of the MKP family, is essential for the
dephosphorylation/deactivation of MAPKs p38 and JNK.
Additionally, it serves as pivotal feedback control regulator
in the innate immune response during microbial infection
and thus, plays a signiﬁcant role in the progression of
periodontitis.
2.2. Expression of Immune Cytokines. Periodontal diseases
are characterized by chronic inﬂammation due to the over-
production of inﬂammatory mediators such as cytokines,
chemokines, nitric oxide, and reactive oxygen species by
immune and nonimmune cells. In the progression of the
disease, the extent and severity of tissue destruction are the
resultofcytokineoverproduction,whichislargelydependent
on the nature of the host-microbial interactions.
Cytokinesinteractfunctionallyinnetworksandintegrate
aspects of innate and adaptive immunity, mobilizing leuko-
cytes to the infection site, initiating the adaptive immune
response, and initiating the acute phase response [16]. To
date, two proinﬂammatory cytokines, TNF-α and IL-1β,a r e
the best understood cytokines that correlate signiﬁcantly
with periodontal diseases.
Of the IL-1 family, IL-1α and IL-1β have been recog-
nized to be central proinﬂammatory cytokines with similar
biological activity. IL-1ra is an endogenous receptor antag-
onist and an anti-inﬂammatory nonsignaling molecule that
competes for receptor binding with IL-1α and IL-1β.T h e
overallcontributionofIL-1totheproinﬂammatoryresponse
depends on the balance among these three molecules [70,
71]. In periodontal research, many studies are conducted
to measure IL-1β in gingival tissue and gingival crevicularJournal of Signal Transduction 5
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Figure 2: MAPK activation and regulation via MKP-1. Bacterial LPS induces MAPK signaling as described in Figure 1. MAP Kinase
Phosphatase-1(MKP-1)negativelyregulatesMAPKactivationviadephosphorylationoftargetkinasesatmultiplepointsofkinaseactivation.
ﬂuid (GCF) in patients with various periodontal conditions.
Increased IL-1β expression has been consistently detected in
both samples [72, 73] and was associated with periodontitis
severity [74], and IL-1β decreased after treatment [75].
In periodontitis patients, IL-1β production increased via
circulating monocytes or oral polymorphonuclear neu-
trophils (PMNs). Furthermore, blockage of IL-1β activity
slowedprogressionofexperimentalperiodontitisinprimates
[76]. In addition, IL-1β stimulates many cells to produce
MMPs and prostaglandins, resulting in bone resorption and
connective tissue degradation, all of which contribute to the
pathogenesis of periodontitis [77].
TNF-α is released by activated monocytes, macrophages,
and T-lymphocytes and promotes critical inﬂammatory
responses. TNF-α induces bone resorption and upregulates
PGE2 and MMP secretion during periodontal disease [56].
Clinical evidence indicates that patients with periodontal
disease have increased TNF-α in the gingival crevice ﬂuid
[44], and TNF-α has been shown to be enhanced during
destruction of periodontal tissues [49–51]. TNF-α binds
to two distinct TNF receptors: TNF-R1 (p55) and TNF-
R2 (p75), and most of TNF’s inﬂammatory activities are
transduced by TNF-R1. TNF-R2 is thought to enhance this
activitybybindingTNFandthenpassingitontotheTNF-R1
[78]. Blocking TNF-α has been proven to eﬀectively inhibit
osteoclast formation [79]. Indeed, the blockade of TNF can
be used as a probe to understand the molecular basis of
osteoclastogenesisanditmaybeatargetfortherapeuticagent
development.
3. Cytokine Inhibition Strategies via
MAPK Blockade
The contemporary concept of periodontal therapy focuses
on eliminating bacteria through mechanical and chemother-
apeutics means because the role of bacteria in the initiation
and progress of periodontal disease is undisputed. Various
therapeutic strategies aimed at the microorganisms, includ-
ing local and systemic delivery of antimicrobial and antibi-
otic agents, have been studied over the years, but none of
thesemethodshasprovenuniversallyeﬃcacious,particularly
in the case of tissue-invasive species such as Aggregatibacter
actinomycetemcomitans (A. actinomycetemcomitans). As we
understand more about the immune response in the patho-
biology of infectious diseases, including periodontitis, ther-
apeutic strategies have focused more on host modulation.
For example, therapeutic manipulation involving inhibition
of TLR signaling using a small molecule inhibitor TAK-242
hasbeendemonstratedtobebeneﬁcialtosepsis[80].Speciﬁc
soluble receptors (antagonists) of IL-1 and TNF-α inhibited
the progression of bone loss by reducing the formation
of osteoclast and recruitment of inﬂammatory cells in a
nonhuman primate experimental periodontitis model [81].
Approaches to block the progression of inﬂammatory bone
loss observed in periodontitis include host modulation of
MMPs, COX2, and arachidonic acid metabolites. However,
these therapies target singular mechanisms of alveolar bone
destruction. Cytokines are well known to compensate for
one another, thereby limiting the eﬀect of cytokine-speciﬁc6 Journal of Signal Transduction
inhibitors. Alternatively, targeting a common regulatory
mechanism for multiple cytokines may repress periodon-
tal disease progression and improve treatment response.
Also, inﬂammatory cell signaling pathways that generate
inﬂammatory and tissue destruction proteins have become
promising therapeutic targets. Therapeutic modulation of
signaling pathways can aﬀect various genes, depending not
only on the pathway but also on the relative position targeted
for inhibition in the signaling cascade. Because the MKK-
MAPK-MK2 pathway phosphorylates downstream inter-
mediates and regulates ARE proinﬂammatory cytokines,
including IL-6, TNF-α, GM-CSF, IL-8, and iNOS, through
mRNA stability, it and its pathway components could be
excellent targets for therapeutic designs.
3.1. p38 Inhibition Studies. As described previously, p38
MAPK is an upstream eﬀector common to many inﬂamma-
tory cytokines. Activation of p38 MAPK signaling mediates
inﬂammatory cytokine expressions such as IL-1β,I L - 6 ,a n d
TNF-α either directly or indirectly. These cytokines syner-
gistically stimulate the production of other inﬂammatory
cytokines, MMPs, and prostanoids [82–86]. p38 has also
been implicated in the regulation of, IL-3, IL-8, macrophage
inhibitory protein 1-α (MIP), GM-CSF, VEGF, urokinase-
type plasminogen activator, and inducible NO synthase [87–
90]. Evidence suggests that it is involved in rheumatoid
arthritis, Alzheimer’s disease, ischemic heart disease, asthma,
dermatitis, inﬂammatory bowel disease, and periodontitis
[86, 91–98].
Four members of the p38 MAPK family have been
cloned: p38-α,- β,- γ,a n d- δ. All isoforms share conserved
residues involved in ATP and ion binding and share signiﬁ-
cant sequence homology in their kinase domain and the 24-
to 27 amino acid N-terminal to this domain. These regions
are most likely to be involved in substrate speciﬁcity and
activity. The α isoform is ubiquitously expressed to induce
apoptosis, whereas the β isoforms is highly expressed in the
brain and heart to promote cell survival in cardiac muscle
cells. The γ isoform is chieﬂy expressed in muscle cells, and
the δ isoform is expressed in the lung, kidney, gut, and
salivary gland epithelium.
Bicyclic imidazole (compound SB203580) was initially
identiﬁed to be an ATP-competitive inhibitor of p38 kinase
[99], and later, more potent and speciﬁc inhibitors such
as VX-745 and BIRB-796 were explored [100]. These
developments lead to p38 kinase inhibition therapies which
have been shown to be eﬃcacious in several animal dis-
ease models, including rheumatoid arthritis (RA), psori-
asis, Crohn’s disease, stroke, asthma, chronic obstructive
pulmonary disease (COPD), and periodontitis [99, 101–
105]. For example, p38 inhibitors SC409 and SD282 have
been shown to be eﬃcacious in reducing and reversing
bone and cartilage destruction in an experimental arthritis
model [91]. In LPS-induced arthritis, mice treated with
p38 MAPK inhibitors RO4399247 and AVE8677 diminished
IL-6 to background levels [106]. Given that cytokines act
synergistically, simultaneously blocking them is substantially
more eﬀective than blocking one alone. In the ﬁrst study
to test p38 inhibitors in humans, a single dose decreased
TNF-α,IL-1,and-6by90%.Amonginhibitors,animportant
distinction among isoforms is their ability to be inhibited by
SB203580. Such inhibitors have 14.3 to >1,000 times greater
activityagainstp38αthanp38β,p38γ,orp38δ isoforms[91].
Research from our laboratory documents the relevance
of p38 MAPK in the regulation of expression of IL-6, MMP-
13, and receptor activator of NF-κB ligand in periodontally
relevant resident cells, such as ﬁbroblasts and osteoblasts,
in vitro [17, 59, 107, 108]. In vivo, we have shown the
signiﬁcance of p38 MAPK signaling in periodontal disease
progression, in which orally active p38 inhibitors reduced
periopathogenic LPS-induced bone destruction in a rat
model [105]. To study the preventive function of p38α
inhibitors in periopathogenic LPS-induced experimental
alveolar bone loss using a rat model, two simultaneous
doses of SD-282 (15 or 45mg/kg) were administered twice
daily by oral gavage for 8 weeks. Bone area and volumetric
analysis by μCT indicated signiﬁcant bone volume loss with
LPS treatment, but this was blocked with both doses of
p38α inhibitor (see Figure 3). Histological examination indi-
cated signiﬁcantly fewer tartrate-resistant acid phosphatase-
positive osteoclasts adjacent to the areas of active bone
resorption, including the periodontal ligament area, and a
signiﬁcant decrease in IL-6, IL-1β,a n dT N F - α expression in
p38 inhibitor-treated groups compared with LPS groups by
immunostaining. This proof-of-principle study supports—
for the ﬁrst time—the role of an orally active p38α MAPK
inhibitor (SD-282) to potentially beneﬁt LPS-induced alveo-
lar bone loss. These data also suggest that the α isoform is the
predominate isoform expressed in LPS-induced periodontal
disease pathology.
Clinically, the therapeutic goal is to prevent further
advancement of alveolar bone loss. Thus, in a second
therapeutic model, we investigated the eﬀect of a p38 MAPK
inhibitor on established periodontal disease [109]. The
periodontal disease state was established by LPS injections
to the palatal molar gingiva three times per week for
4w e e k s .p 3 8 α MAPK inhibitor SD282 (45mg/kg) was
administrated from weeks 5 through 8 via oral gavage in
addition to LPS injections. The data from this study revealed
that treatment with an orally active p38 MAPK inhibitor
stopped the established periodontal disease progression in
vivo and decreased inﬂammatory cytokine (IL-1β,T N F -
α) expression and osteoclastogenesis. Interestingly, in this
study, SD282 had a slight anabolic eﬀect; the diﬀerence
between the 8-week LPS-only and LPS + SD282 groups was
signiﬁcant for increased bone volume. The reasons for this
are unclear and may be due to a relatively high suppression
of osteoclastogenesis without compensatory cessation of
osteoblastic diﬀerentiation. Conceptually, this makes p38
inhibitor strategies appealing as a host-modulating agent
for treatment of periodontitis because physiologic bone
turnover(inducedbyPTH/PTHrP)wouldoccur,butinﬂam-
matoryboneloss(inducedbyLPS,IL-1β,andTNF -α)w ould
be pharmacologically antagonized.
Collectively, these data highlight the therapeutic poten-
tial of this novel class of inhibitors in bacterial-induced
alveolar bone loss—the hallmark of periodontitis, but devel-
opingp38inhibitorsasatherapeuticsinclinicalsettingshaveJournal of Signal Transduction 7
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Figure 3: A. actinomycetemcomitans LPS induces signiﬁcant linear bone loss which is blocked by SD-282. (a) Reformatted μCT isoform
display from 8 weeks A. actinomycetemcomitans LPS-injected rat maxillae exhibits dramatic palatal and interproximal bone loss. Landmarks
usedforlinearmeasurementswerethecementoenameljunction(CEJ)tothealveolarbonecrest(ABC).Diﬀerencesbetweentheseanatomical
locations using deﬁned locations of 2D displays determined alveolar bone loss. (b) Linear bone loss as measured from the CEF to AB (Mean
± SEM). Signiﬁcant bone loss (P<0.01) was observed between control (n = 6) and A. actinomycetemcomitans LPS injected rats (n = 12).
Signiﬁcant reduction of LPS-induced periodontal bone loss (∗∗P<0.01 for SD-282 [15mg/kg; n = 8] and ∗P<0.05 for SD-282 [45mg/kg;
n = 8]) [105]. Reproduced with permission.
failed due to unacceptable safety proﬁles, central role for
activation of various downstream kinases and transcription
factors, ubiquitous expression, toxicity, signiﬁcant oﬀ-target
eﬀects, and lack of oral bioavailability [110]. Preclinical
andclinicalsideeﬀectsincludehepatotoxicity,cardiotoxicity,
light-headedness,centralnervoussystemtoxicities,skinrash,
gastrointestinal tract symptoms, and bacterial infections
[88, 111–115]. In addition, p38 MAPK-knockout mouse is
embryonic lethal [90, 116–118]. Until now none of these p38
inhibitors has been approved for clinical usage.
3.2. Intraoral Silencing of MK2 Signaling. Due to the con-
cerns about p38 inhibitors indicated above, targeting down-
stream substrates of p38 MAPK and factors that regulate
transcription, nuclear export, mRNA stability, and trans-
lation could be a promising therapeutic alternative for
inhibiting inﬂammatory gene expression to treat various
inﬂammatory diseases. As a direct substrate of the stress-
activated MAPK p38α and β[119], MAPK-activated protein
kinase 2 (MAPKAPK-2, MK2) is regulated exclusively by
p38α/β [119].
Landmark studies performed with MK2-deﬁcient cells in
vitro or with MK2-deﬁcient mice in vivo clearly revealed the
physiologicalrolesofMK2activation.Thestudiesperformed
with MK2-deﬁcient cells in vitro demonstrated a central role
of MK2 in the production of proinﬂammatory mediators
such as TNF-α,I L - 1 β,M I P - 1 α, IL-8, IL-6, and INFγ
[120]. MK2 is also involved in atherogenesis by promoting
the recruitment of inﬂammatory monocytes/macrophages
through increasing endothelial expression of VCAM-1 and
MCP-1 [121]. MK2-deﬁcient mice show an increased stress
resistance to LPS-induced endotoxic shock, owing to a
severely impaired inﬂammatory response leading to a 90%
reduction in TNF-α p r o d u c t i o n ,a sw e l la sr e d u c t i o no f
IFN-γ,I L - 1 β, IL-6, and nitric oxide [120]. The MK2 gene
deletion protected DBA/1LacJ mice from collagen-induced
arthritis due to a signiﬁcantly lower LPS-induced TNF-α and
IL-6 serum levels when compared with wild-type controls
[122]. Deﬁciency of MK2 also protected against cerebral
ischemic injury [123]. In addition, MK2 also participates
in other diverse cellular processes such as cell division,
apoptosis, cell diﬀerentiation, endocytosis, reorganization
of the cytoskeleton, cell migration, cell cycle progression,
chromatin remodeling, respiratory burst, and chemotaxis
[124–126].
Targeting MK2 should be a more speciﬁc target than
p38, with potentially fewer side eﬀects, because MK2 acts on
a more limited downstream substrate repertoire compared
to p38. Importantly, MK2-deﬁcient mice are viable with
a normal phenotype [90, 120]. Therefore, there has been
much research exploiting MK2 as molecular target for the
development of experimental therapeutics for number of
conditions such as RA, Alzheimer’s disease, atherosclerosis,
and cancer. As periodontal disease has remarkably similar8 Journal of Signal Transduction
inﬂammatory pathways and mediator proﬁles with other
inﬂammatory diseases [6, 127, 128], it is reasonable to
anticipate that MK2 would be an attractive and potentially
selective target for the treatment of periodontitis. However,
targeting MK2 with small molecular inhibitors is complex
and diﬃcult because of the relatively planar ATP-binding site
of this critical MAPK.
In our study, we hypothesized that silencing MK2
through an RNAi strategy would provide a novel anti-
inﬂammatory target that selectively blocks signaling mech-
anisms needed for enhanced cytokine mRNA stabil-
ity/translation in periodontitis progression. First, we val-
idated MK2 silencing in cytokine production in vitro to
evaluate the feasibility of choosing MK2, instead of p38, as
a highly speciﬁc and potent drug candidate. Our data clearly
showed that LPS-induced IL-6 expression was signiﬁcantly
attenuated, both at the mRNA and protein levels, a result
consistent with previous observations in MK2−/−mice [120,
122]. We observed that MK2 siRNA delivery signiﬁcantly
reduced TNF-α mRNA and protein expression. The role
of MK2 in the regulation of LPS-induced inﬂammatory
cytokine gene expression is further conﬁrmed by signiﬁcant
reductions of mRNA expression for COX-2, IL-1β, and the
chemokine CXCL1 in cells transfected with MK2 siRNA.
MK2 siRNA gene knockdown changed the activation of JNK
and ERK MAPKs without obvious phospho-p38 expression
variation, suggesting the existence of crosstalk and com-
pensatory mechanisms and underscoring the complexities
of Toll-like receptor signaling pathways. Secondly, in vivo
studies employed the rat LPS-induced experimental peri-
odontitis model to further elucidate the role of MK2 in the
pathogenesis of periodontitis and evaluate the therapeutic
potential by targeting MK2 employing an RNAi strategy
in periodontal disease. The protection of MK2 siRNA
from alveolar bone loss in LPS-induced periodontitis model
was further veriﬁed by μCT analysis (see Figure 4;[ 129]).
Histological examination displayed that MK2 siRNA in vivo
delivery attenuated the inﬂammatory inﬁltrate associated
with A. actinomycetemcomitans LPS-induced bone loss. This
is consistent with the decrease of osteoclast formation after
MK2 silencing. In conclusion, with an RNAi strategy, our
recent work validated that MK2 plays a role in a preventive
model of experimental periodontitis, suggesting a novel
target for controlling periodontal inﬂammation.
3.3. MKP-1 Alters MAPK Signaling in Periodontal Disease
Progression. MAPKs are activated by phosphorylation of
critical tyrosine, serine, or threonine residues. Negative
regulation of MAPK activity is mediated by the MAPK
phosphatases (MKPs) that dephosphorylate these functional
residues [130]. To date, this group of dual-speciﬁcity protein
phosphatases (MKPs) includes 11 members in mammalian
cells and the founding member is MKP-1. MKP-1 is localized
to the nucleus, where it preferentially dephosphorylates
activated p38 and JNK compared with ERK MAPK [131].
In vitro studies conducted using cultured immortalized
macrophages provided compelling evidence that MKP-1
attenuates TNF-α and IL-6 after LPS stimulation [132–134].
MKP-1 functions as a feedback control mechanism, which
governs the production of proinﬂammatory cytokines by
deactivating p38 andJNK, therebylimiting proinﬂammatory
cytokine biosynthesis in innate immune cells exposed to
microbial components [132, 133, 135]. Consistent with in
vitro data, MKP-1 null mice had markedly more production
of proinﬂammatory cytokine TNF-α, IL-6, and an anti-
inﬂammatory cytokine IL-10 compared with wild-type
animals. Sustained p38 and JNK activity in response to
stress support the central role of MKP-1 in the restraint
of the innate immune response and in the prevention of
endotoxemia, experimentally induced autoimmune arthritis,
septic shock syndrome, and multiorgan dysfunction during
pathogenic microbial infection [134–138].
T h ec r i t i c a lr o l eo ft h ep 3 8 / M K P - 1a x i so fr e g u l a t i o n
on the innate immune response and in maintaining bone
homeostasis has been clearly demonstrated. Moreover, as
MKP-1 not only regulates p38 MAPK, but also JNK and
ERK activities, overexpression of MKP-1 has potent capacity
to prevent an exuberate immune response and osteoclasto-
genesis in response to stimuli compared with p38 MAPK
inhibitors. Using gain- and loss-of-function approaches,
the role and potential therapeutic target of MKP-1 in
inﬂammatory bone loss was explored.
First, decreased IL-6 expression was observed in murine
macrophage cell line RAW264.7 transfected with expression
vector containing MKP-1 cDNA in pSRII-Flag. This data
provided in macrophages supports the role of MKP-1 in neg-
ative regulation of A. actinomycetemcomitans LPS-induced
p38 activation and IL-6 production [139]. MKP-1 plays a
crucial role in decreasing inﬂammatory cytokine biosynthe-
sis. Then in our chronic periodontitis model, wild-type and
MKP-1 null mice received A. actinomycetemcomitans LPS
injection in the palatal region or PBS control 3 times/wk
for 30 days. Results indicated that, in LPS injected MKP-
1−/− mice, signiﬁcantly greater bone loss occurred with more
inﬂammatory inﬁltrate in the periodontal areas injected
with LPS and a signiﬁcant increase in osteoclastogenesis
compared with MKP-1−/− control sites or either wild-type
littermates. MKP-1 displayed a protective response in this
more chronic model of inﬂammation and bone loss [139].
In gain-of-function experiments, MKP-1 was able to
dephosphorylation allthreeMAPKsviaMKP-1genetransfer
with recombinant adenovirus MKP-1 in rat macrophages.
Ex vivo data indicated that MKP-1 gene transfer in bone
marrow macrophages from MKP-1 KO mice signiﬁcantly
decreased IL-6, IL-10, TNF-α, and select chemokine levels
compared with wild-type mice when stimulated by LPS
[140]. In addition, bone marrow cultures from MKP-1
KO mice exhibited signiﬁcantly more osteoclastogenesis
induced by LPS than when compared with WT mice. This
observation correlated with more osteoclasts seen in bone
marrow cells of MKP-1 KO mice compared with osteoclasts
from WT mice in response to LPS stimuli. Furthermore, in
vivo MKP-1 gene transfer in an experimental periodontal
disease model attenuated bone resorption induced by LPS
(See Figure 5;[ 140]). Histological analysis conﬁrmed that
periodontal tissues transduced with Ad. MKP-1 exhibited
less inﬁltrated inﬂammatory cells, less osteoclasts, and less
IL-6 than compared with rats of control groups.Journal of Signal Transduction 9
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Figure 5: MKP-1 gene transfer alleviated bone resorption in rats after LPS challenge. Eight-week-old male Sprague-Dawley rats (17
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Together, our studies indicate the importance of MKP-
1 in the development of immune responses that contribute
to LPS-induced alveolar bone loss. It can be used as a key
therapeutic target to control of inﬂammation-induced bone
loss associated with increased MAPK activation.
3.4. Local Gene Delivery of TTP as an Anti-Inﬂammatory
Agent. Cells of the immune system tightly regulate the
production of potentially harmful cytokines at many lev-
els: transcriptional, posttranscriptional, translational, and
posttranslational levels. Posttranscriptional regulation of
cytokines occurs at diﬀerent stages such as nuclear export,
cytoplasmic localization, and stability/degradation. Central
to the posttranscriptional regulatory events is the interaction
of RNA with RNA-binding proteins that inﬂuence their
splicing, localization, stability, and association with the
translation machinery [141–143].
The cisacting elements, which interacted with RNA-
binding protein, are AU-rich elements (AREs) [67, 144].
They are located in the 3  untranslated regions (UTRs)
of many cytokines (e.g., granulocyte-macrophage colony-
stimulating factor (GM-CSF), TNF-α, IL-2, IL-3, IL-6),
and other proinﬂammatory factors (e.g., COX2 and MMP-
13). A hallmark of AREs is the pentamer AUUUA that
occurs either alone or clustered [145]. Recently, the struc-
ture and the functional signiﬁcance of AREs have been
clearly demonstrated by insertion strategy and deletion
strategy.
At least 20 diﬀerent proteins that can bind to ARE
segments have been identiﬁed to date, including TTP, HuR,
butyrate response factor (BRF)-1 and BRF-2, ARE/poly(U)-
binding/degradation factor-1 (AUF-1), T-cell intracellu-
lar antigen-1 (TIA-1), and T-cell-restricted intracellular
antigen-related protein (TIAR). However, only a subset
of RNA-BPs has been shown to inﬂuence the stability or
translationaleﬃciencyoftargetmRNAs.SomeRNA-binding
proteins, such as TTP, AU-binding factor 1, and K homology
splicing-regulatory protein, promote mRNA decay, whereas
others, like members of the Hu family, prevent mRNA
degradation.
TTP is a well-characterized, zinc-ﬁnger-containing,
RNA-binding protein. The function of TTP was elucidated
through several studies with TTP-deﬁcient mice. TTP deﬁ-
ciency is associated with cachexia, arthritis, autoimmunity,
and myeloid hyperplasia, secondary to increased TNF-α and
GM-CSF levels. In TTP−/− mice, the increased cytokine
production was shown to be a result of increased mRNA
stability [66, 146]. Many studies also have demonstrated that
the overexpression of TTP promoted the decay of reporter
transcripts that contained AU-rich sequences from TNF-α in
vitro [147].
TTP binds to AREs located in 3  untranslated regions of
cytokine genes and targets them to the exosome for rapid
degradation. In this context, TTP can be considered an anti-
inﬂammatory protein. As a point of therapeutic potential,
we hypothesized that targeting a common upstream RNA-
binding protein, TTP, may inhibit periodontitis progression.
Usingadenoviral-deliveredTTP,TTPoverexpressionwas
evaluated in a preventive model of experimental periodonti-
tis to determine whether altering cytokine mRNA stabilityJournal of Signal Transduction 11
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Figure 6: Ad5-TTP protects bone in experimental periodontal disease model. (a) representative microcomputed tomography images of
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with permission.
aﬀected pathological bone resorption (see Figure 6;[ 148]).
In vivo analysis indicated a signiﬁcant protective eﬀect from
inﬂammation-induced bone loss and inﬂammatory inﬁltrate
in animals overexpressing TTP compared with reporter
controls. In addition, signiﬁcant reductions of IL-6, TNF-
α,a n dP G E 2 were observed after TTP overexpression in
vitro through a mechanism consistent with targeting mRNA
stability. Collectively, these ﬁndings provide experimental12 Journal of Signal Transduction
evidence that mRNA stability is a valid therapeutic target in
inﬂammatory bone loss.
In vitro, we focused on testing if p38/MK2 signaling is
requiredforcytokinesexpressionregulationviaTTPactivity.
Using MC3T3-E1 cell line as an osteoblastic model, we
observed that p38 MAPK regulates IL-1β-stimulated IL-6
at a posttranscriptional mechanism and one of the primary
targets of IL-6 gene regulation is the 3  UTR of IL-6 [107].
Using mouse embryonic ﬁbroblasts (MEFs) derived from
p38α−/− mice, we further conﬁrmed the above conclusion
and determined p38α as the critical isoform. We identiﬁed
three ARE elements that require p38α signaling, and IL-
63  -UTR-(56–173) is critical for p38α to promote mRNA
stability [149]. After this, the role of TTP in posttranscrip-
tional regulation of IL-6 was elucidated. Genetic and siRNA-
mediated knockdown of TTP resulted in increased IL-6
production and overexpression of TTP had the reverse eﬀect
[150]. Signiﬁcant IL-6 mRNA expression and a long half-
life were observed in TTP−/− mice MEFs. Overexpression of
TTP reduced IL-6 3 UTR luciferase reporter activity in an
ARE-dependent manner. Mutation-based luciferase assays
show that ARE2, ARE3, and ARE4 are required for TTP-
mediated repression, and the constitutively activated p38-
MK2 pathway abrogated TTP-mediated repression of IL-
63  UTR reporter activity. An RNA immunoprecipitation
assay indicated that the p38α deﬁciency resulted in increased
aﬃnity of TTP to IL-6 mRNA. Taken together, our serial
studies showed that the RNA-binding protein, TTP, regulates
IL-1β-induced IL-6 expression at the posttranscriptional
level through an aﬃnity shift for the transcript, which occurs
in a p38 MAPK-dependent manner and involves speciﬁc
AREs within the 3 UTR of the IL-6 mRNA.
4. FutureStudies
Our research group has accumulated signiﬁcant information
that IL-6 regulation is highly dependent on p38 MAPK
signaling in a variety of cell types [59, 105, 107, 108, 149,
151]. TTP directs mRNA stability of IL-6 largely in a p38
MAPK-dependent manner [150]. The clinical signiﬁcance of
this regulation was also demonstrated through inhibition of
inﬂammation and bone loss via diﬀerent strategies, such as
small molecule inhibitors against p38 MAPK [105], MKP-
1 overexpression, or TTP overexpression using gene transfer
with recombinant adenovirus MKP-1 or TTP [140, 148,
149], and more recently using siRNA strategies targeting
the p38 downstream kinase, MK2 [129]. Collectively, our
series of studies targeting multiple molecules situated in
inﬂammatory-related MAPK signaling cascade either to elu-
cidate the functional mechanism or to verify the therapeutic
potential for periodontal disease provide strong proof-of-
principle evidence.
However, disease progression is complex with multiple
aspects worthy of consideration. In human periodontal
pathology, infectious bacteria are capable of interacting
with the host. Although LPS is a potent inﬂammatory
mediator, other components (e.g., cytoplasmic membranes,
peptidoglycans,outermembraneproteins,capsules,andcell-
surface ﬁmbriae) within live organisms can induce apoptosis
and modulate or evade the immune response. In addition,
other classes of PRRs, such as Nod-like receptors (NLRs),
have been recognized to have important roles in sensing
intracellular infections [152]. NLRs have also been shown to
modulate various signaling pathways, including p38 MAPK
and NF-κB, underscoring the complexity of TLR signaling
and the crosstalk with other signaling pathways involved
in the pathobiology of periodontal disease. Cytokines in
the periodontium integrate aspects of innate and adaptive
immunity. It is becoming clear, however, that cytokines
do not function in isolation, but form complex interactive
networks involving both pro- and anti-inﬂammatory eﬀects.
Future studies are being planned with large animals or
nonhuman primates to further address the therapeutic eﬀect
of small molecule inhibitor strategies. In addition, elucida-
tion of fundamental mechanisms, ﬁnding powerful target
candidates, developing clinically viable delivery systems, and
optimizingdoseanddeliveryroutesmustbeaddressed,along
with exploration of diﬀerent infection models to elucidate
the potential of these strategies to arrest other inﬂammatory
diseases.
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